The Suppression of the SPHK1/S1P/S1PR3 Signaling Pathway Diminishes EGFR Activation and Increases the Sensitivity of Non-small Cell Lung Cancer to Gefitinib

Overview

Journal Curr Res Pharmacol Drug Discov

Date 2025 Feb 3

PMID 39896887

Authors

Jing Zhang

Zequn Wang

Xihua Wei

Mengyuan Han

Ribai Yan

Lijie Ma

Yan Pan

Affiliations

Soon will be listed here.

Abstract

Non-small-cell lung cancer (NSCLC) represents a predominant histological subtype of lung cancer, characterized by high incidence and mortality rates. Despite significant advancements in therapeutic strategies and a deeper understanding of targeted therapies in recent years, tumor resistance remains an inevitable challenge, leading to poor prognostic outcomes. Several studies have indicated that sphingosine kinase 1 (SPHK1) plays a regulatory role in epidermal growth factor receptor (EGFR) signaling, and its elevated expression may be associated with resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Furthermore, the catalytic product of SPHK1, sphingosine 1-phosphate (S1P), along with its receptor, sphingosine 1-phosphate receptor 3 (S1PR3), plays a regulatory role in the function of the EGFR. However, the specific effects of the SPHK1/S1P/S1PR3 axis on EGFR in NSCLC, as well as the combined effects of SPHK1/S1P/S1PR3 inhibitors with the EGFR-TKI gefitinib, remain to be elucidated. In the present study, we investigated the correlation between SPHK1 expression levels and the survival rates of NSCLC patients, the relationship between SPHK1 or S1PR3 and EGFR, and the impact of SPHK1 expression on the half-maximal inhibitory concentration (IC) of gefitinib in NSCLC. In A549 cells, the phosphorylation of EGFR was significantly reduced following SPHK1 knockdown. Utilizing SPHK1/S1P/S1PR3 inhibitors, namely PF543, TY52156, and FTY720, we established that the SPHK1/S1P/S1PR3 axis modulates EGFR activation in NSCLC. Furthermore, these signaling inhibitors enhanced the anti-proliferative efficacy of the EGFR-TKI gefitinib. RNA sequencing analysis revealed substantial alterations in 85 differentially expressed genes in NSCLC cells treated with the combination of FTY720 and gefitinib. These genes were predominantly associated with pathways such as axon guidance, microRNAs in cancer, and the JAK-STAT signaling pathway, among others. Overall, targeting the SPHK1/S1P/S1PR3 signaling pathway represents a promising therapeutic strategy to enhance gefitinib sensitivity in NSCLC.

References

Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S . Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2007; 112(1):41-52. DOI: 10.1007/s10549-007-9836-9. View

Martin J, de Silva H, Lin M, Scott C, Baxter R . Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther. 2013; 13(2):316-28. DOI: 10.1158/1535-7163.MCT-13-0367. View

French K, Schrecengost R, Lee B, Zhuang Y, Smith S, Eberly J . Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63(18):5962-9. View

Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F . Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol. 2006; 173(2):301-10. PMC: 2063820. DOI: 10.1083/jcb.200506033. View

Hsu A, Zhang W, Lee J, An J, Ekambaram P, Liu J . Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol. 2012; 40(5):1619-26. PMC: 3797598. DOI: 10.3892/ijo.2012.1379. View

Lin Z, Li Y, Han X, Fu Z, Tian Z, Li C . Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer. Int J Mol Sci. 2022; 23(21). PMC: 9657307. DOI: 10.3390/ijms232112741. View

Passaro A, Janne P, Mok T, Peters S . Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2022; 2(4):377-391. DOI: 10.1038/s43018-021-00195-8. View

Ke B, Wei T, Huang Y, Gong Y, Wu G, Liu J . Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2. Mediators Inflamm. 2020; 2019:7241418. PMC: 6931030. DOI: 10.1155/2019/7241418. View

White C, Alshaker H, Cooper C, Winkler M, Pchejetski D . The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016; 7(17):23106-27. PMC: 5029614. DOI: 10.18632/oncotarget.7145. View

10.

Hamada M, Kameyama H, Iwai S, Yura Y . Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017; 3:17047. PMC: 5554793. DOI: 10.1038/cddiscovery.2017.47. View

11.

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

12.

Schiefler C, Piontek G, Doescher J, Schuettler D, Misslbeck M, Rudelius M . Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk. Oncotarget. 2014; 5(20):9877-88. PMC: 4259444. DOI: 10.18632/oncotarget.2436. View

13.

Lin C, Lee I, Hsu C, Hsu C, Chi P, Hsiao L . Sphingosine-1-phosphate mediates ICAM-1-dependent monocyte adhesion through p38 MAPK and p42/p44 MAPK-dependent Akt activation. PLoS One. 2015; 10(3):e0118473. PMC: 4348486. DOI: 10.1371/journal.pone.0118473. View

14.

Gupta P, Kadamberi I, Mittal S, Tsaih S, George J, Kumar S . Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer. Adv Sci (Weinh). 2022; 9(14):e2104452. PMC: 9108620. DOI: 10.1002/advs.202104452. View

15.

Chun J, Hartung H . Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33(2):91-101. PMC: 2859693. DOI: 10.1097/WNF.0b013e3181cbf825. View

16.

Yan Y, Bao G, Pei J, Cao Y, Zhang C, Zhao P . NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progression. Biochim Biophys Acta Mol Basis Dis. 2022; 1868(7):166401. DOI: 10.1016/j.bbadis.2022.166401. View

17.

Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E . Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Cancer Sci. 2013; 104(11):1483-91. PMC: 7654259. DOI: 10.1111/cas.12266. View

18.

Kim S, Kwon O, Hong Y, Kim J, Solca F, Ha S . Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012; 11(10):2254-64. DOI: 10.1158/1535-7163.MCT-12-0311. View

19.

Wang S, Liang Y, Chang W, Hu B, Zhang Y . Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis. Med Sci Monit. 2018; 24:1912-1923. PMC: 5894569. DOI: 10.12659/msm.905833. View

20.

Song L, Xiong H, Li J, Liao W, Wang L, Wu J . Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res. 2011; 17(7):1839-49. DOI: 10.1158/1078-0432.CCR-10-0720. View